Garland L, Robinson L A, Wagner H
Thoracic Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, Florida, USA.
Chest Surg Clin N Am. 2001 Feb;11(1):69-100, viii.
Management of the stage IIIA (N2) patient remains one of the most controversial areas in thoracic oncology. The potential curability of at least some of these patients has encouraged the development of more complex, aggressive, and toxic multimodality treatment regimens.
IIIA期（N2）患者的管理仍然是胸科肿瘤学中最具争议的领域之一。这些患者中至少有一部分具有潜在的可治愈性，这促使了更复杂、积极且毒性更大的多模式治疗方案的发展。
